| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Minireview
Altered Hsp90 function in cancer: A unique therapeutic opportunity
Steele Memorial Children's Research Center and Arizona Cancer Center, University of Arizona, Tucson, Arizona
Requests for reprints: Luke Whitesell, Department of Pediatrics and Hematology/Oncology, Arizona Health Sciences Center, Room 5341, 1501 North Campbell Avenue, Tucson, AZ 85724. Phone: 520-626-4851; Fax: 520-626-6986. E-mail: whitelj{at}peds.arizona.edu
Molecular chaperones or so-called heat shock proteins serve as central integrators of protein homeostasis within cells. In performing this function, they guide the folding, intracellular disposition, and proteolytic turnover of many key regulators of cell growth, differentiation, and survival. Recent data show essential roles for the chaperones in facilitating malignant transformation at the molecular level and support the concept that their altered utilization during oncogenesis is critical to the development of human cancers. The field is evolving rapidly, but it has become apparent that chaperones can serve as biochemical buffers at the phenotypic level for the genetic instability that is characteristic of many human cancers. Chaperone proteins thus allow tumor cells to tolerate the mutation of multiple critical signaling molecules that would otherwise be lethal. Much of the recent progress in understanding the complex role of heat shock proteins in tumorigenesis has been made possible by the discovery of several natural product antitumor antibiotics that selectively inhibit the function of the chaperone Hsp90. These agents have been used as probes to define the biological functions of Hsp90 at the molecular level and to validate it as a novel target for anticancer drug action. One of these agents, 17-allylamino,17-demethoxygeldanamycin (NSC 330507) has begun phase II clinical trials, and several second-generation compounds are now in late preclinical development. The best way to use Hsp90 inhibitors as anticancer agents remains to be defined. Trials accomplished to date, however, serve as proof of principle that Hsp90 function can be modulated pharmacologically without undue toxicity in humans. Given the redundancy and complexity of the signaling pathway abnormalities present in most cancers, the ability of Hsp90 inhibitors to alter the activity of multiple aberrant signaling molecules instead of just one or two (as most current-generation molecular therapeutics have been designed to do) may prove of unique therapeutic benefit.
3 L. Whitesell, unpublished data.
Received 2/17/04; revised 4/15/04; accepted 5/12/04.
This article has been cited by other articles:
|
|
 |
|
  W.-Y. Chen, F.-R. Chang, Z.-Y. Huang, J.-H. Chen, Y.-C. Wu, and C.-C. Wu Tubocapsenolide A, a Novel Withanolide, Inhibits Proliferation and Induces Apoptosis in MDA-MB-231 Cells by Thiol Oxidation of Heat Shock Proteins J. Biol. Chem., June 20, 2008; 283(25): 17184 - 17193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. I. Morimoto Proteotoxic stress and inducible chaperone networks in neurodegenerative disease and aging Genes & Dev., June 1, 2008; 22(11): 1427 - 1438. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hernandez, G. Lopez-Lluch, J. A. Bernal, P. Navas, and J. A. Pintor-Toro Dicoumarol down-regulates human PTTG1/Securin mRNA expression through inhibition of Hsp90 Mol. Cancer Ther., March 1, 2008; 7(3): 474 - 482. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Bae, C. Mitsiades, Y.-T. Tai, R. Bertheau, M. Shammas, R. B. Batchu, C. Li, L. Catley, R. Prabhala, K. C. Anderson, et al. Phenotypic and Functional Effects of Heat Shock Protein 90 Inhibition on Dendritic Cell J. Immunol., June 15, 2007; 178(12): 7730 - 7737. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Xu and L. Neckers Targeting the Molecular Chaperone Heat Shock Protein 90 Provides a Multifaceted Effect on Diverse Cell Signaling Pathways of Cancer Cells Clin. Cancer Res., March 15, 2007; 13(6): 1625 - 1629. [Full Text] [PDF]
|
|
|
|
|
|
B. J. Weigel, S. M. Blaney, J. M. Reid, S. L. Safgren, R. Bagatell, J. Kersey, J. P. Neglia, S. P. Ivy, A. M. Ingle, L. Whitesell, et al. A Phase I Study of 17-Allylaminogeldanamycin in Relapsed/Refractory Pediatric Patients with Solid Tumors: A Children's Oncology Group Study Clin. Cancer Res., March 15, 2007; 13(6): 1789 - 1793. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Matei, M. Satpathy, L. Cao, Y.-C. Lai, H. Nakshatri, and D. B. Donner The Platelet-derived Growth Factor Receptor {alpha} Is Destabilized by Geldanamycins in Cancer Cells J. Biol. Chem., January 5, 2007; 282(1): 445 - 453. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. G. Mimnaugh, W. Xu, M. Vos, X. Yuan, and L. Neckers Endoplasmic Reticulum Vacuolization and Valosin-Containing Protein Relocalization Result from Simultaneous Hsp90 Inhibition by Geldanamycin and Proteasome Inhibition by Velcade Mol. Cancer Res., September 1, 2006; 4(9): 667 - 681. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Y. Chen and W. E. Balch The Hsp90 Chaperone Complex Regulates GDI-dependent Rab Recycling Mol. Biol. Cell, August 1, 2006; 17(8): 3494 - 3507. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Fiskus, M. Pranpat, P. Bali, M. Balasis, S. Kumaraswamy, S. Boyapalle, K. Rocha, J. Wu, F. Giles, P. W. Manley, et al. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells Blood, July 15, 2006; 108(2): 645 - 652. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Elisei, A. Vivaldi, R. Ciampi, P. Faviana, F. Basolo, F. Santini, C. Traino, F. Pacini, and A. Pinchera Treatment with Drugs Able to Reduce Iodine Efflux Significantly Increases the Intracellular Retention Time in Thyroid Cancer Cells Stably Transfected with Sodium Iodide Symporter Complementary Deoxyribonucleic Acid J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2389 - 2395. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. K. Nguyen, M. Rahmani, N. Gao, L. Kramer, A. S. Corbin, B. J. Druker, P. Dent, and S. Grant Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate. Clin. Cancer Res., April 1, 2006; 12(7 Pt 1): 2239 - 2247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Sanderson, M. Valenti, S. Gowan, L. Patterson, Z. Ahmad, P. Workman, and S. A. Eccles Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis. Mol. Cancer Ther., March 1, 2006; 5(3): 522 - 532. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. V. Georgakis, Y. Li, G. Z. Rassidakis, H. Martinez-Valdez, L. J. Medeiros, and A. Younes Inhibition of Heat Shock Protein 90 Function by 17-Allylamino-17-Demethoxy-Geldanamycin in Hodgkin's Lymphoma Cells Down-Regulates Akt Kinase, Dephosphorylates Extracellular Signal-Regulated Kinase, and Induces Cell Cycle Arrest and Cell Death Clin. Cancer Res., January 15, 2006; 12(2): 584 - 590. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Guo, K. Rocha, P. Bali, M. Pranpat, W. Fiskus, S. Boyapalle, S. Kumaraswamy, M. Balasis, B. Greedy, E. S. M. Armitage, et al. Abrogation of Heat Shock Protein 70 Induction as a Strategy to Increase Antileukemia Activity of Heat Shock Protein 90 Inhibitor 17-Allylamino-Demethoxy Geldanamycin Cancer Res., November 15, 2005; 65(22): 10536 - 10544. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Guo, P. Reigan, D. Siegel, J. Zirrolli, D. Gustafson, and D. Ross Formation of 17-Allylamino-Demethoxygeldanamycin (17-AAG) Hydroquinone by NAD(P)H:Quinone Oxidoreductase 1: Role of 17-AAG Hydroquinone in Heat Shock Protein 90 Inhibition Cancer Res., November 1, 2005; 65(21): 10006 - 10015. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Chung, S. Lee, E. A. Sausville, Q. Ryan, J. E. Karp, I. Gojo, W. G. Telford, M.-J. Lee, H. S. Kong, and J. B. Trepel Histone Deacetylase Inhibitor Pharmacodynamic Analysis by Multiparameter Flow Cytometry Ann. Clin. Lab. Sci., October 1, 2005; 35(4): 397 - 406. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Castro, C. E. Prada, O. Loria, A. Kamal, L. Chen, F. J. Burrows, and T. J. Kipps ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia Blood, October 1, 2005; 106(7): 2506 - 2512. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. E. Cowen and S. Lindquist Hsp90 Potentiates the Rapid Evolution of New Traits: Drug Resistance in Diverse Fungi Science, September 30, 2005; 309(5744): 2185 - 2189. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Westerheide and R. I. Morimoto Heat Shock Response Modulators as Therapeutic Tools for Diseases of Protein Conformation J. Biol. Chem., September 30, 2005; 280(39): 33097 - 33100. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K-M Rau, H-Y Kang, T-L Cha, S A Miller, and M-C Hung The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers Endocr. Relat. Cancer, September 1, 2005; 12(3): 511 - 532. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Bali, M. Pranpat, J. Bradner, M. Balasis, W. Fiskus, F. Guo, K. Rocha, S. Kumaraswamy, S. Boyapalle, P. Atadja, et al. Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90: A NOVEL BASIS FOR ANTILEUKEMIA ACTIVITY OF HISTONE DEACETYLASE INHIBITORS J. Biol. Chem., July 22, 2005; 280(29): 26729 - 26734. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. T. Price, J. M.W. Quinn, N. A. Sims, J. Vieusseux, K. Waldeck, S. E. Docherty, D. Myers, A. Nakamura, M. C. Waltham, M. T. Gillespie, et al. The Heat Shock Protein 90 Inhibitor, 17-Allylamino-17-demethoxygeldanamycin, Enhances Osteoclast Formation and Potentiates Bone Metastasis of a Human Breast Cancer Cell Line Cancer Res., June 1, 2005; 65(11): 4929 - 4938. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
